Celcuity (CELC) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celcuity Reports Fourth Quarter and Full Year 2017 Financial Results
March 15, 2018 4:00 PM EDTMINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (Nasdaq: CELC) a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the fourth quarter and year ended December 31, 2017.
Unless otherwise stated, all comparisons are for the fourth quarter and year ended December 31, 2017, compared to the fourth quarter and year ended December 31, 2016.
Celcuity reported a net loss of $1.7 million, or $0.17 per share, for the fourth quarter of 2017, compared to a net loss of $0.9 million,... More
